← Back to Screener
Immunovant, Inc. Common Stock (IMVT)
Price$31.11
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)20.89%
Price vs S&P 500 (4W)7.51%
VGM Score72.95
Market Capitalization$6.39B
All Metrics
Book Value / Share (Quarterly)$4.18
P/TBV (Annual)13.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.00
Price vs S&P 500 (YTD)14.23%
EPS (TTM)$-2.77
10-Day Avg Trading Volume1.68M
EPS Excl Extra (TTM)$-2.77
EPS (Annual)$-2.77
ROI (Annual)-59.30%
Cash / Share (Quarterly)$4.42
ROA (Last FY)-52.83%
EBITD / Share (TTM)$-2.92
ROE (5Y Avg)-50.27%
Cash Flow / Share (Annual)$-2.00
P/B Ratio7.49x
P/B Ratio (Quarterly)5.93x
Net Income / Employee (Annual)$-1,396,700
Net Interest Coverage (TTM)-104.22x
ROA (TTM)-62.16%
EPS Incl Extra (Annual)$-2.77
Current Ratio (Annual)9.09x
Quick Ratio (Quarterly)8.68x
3-Month Avg Trading Volume1.66M
52-Week Price Return94.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.92
52-Week High$36.28
EPS Excl Extra (Annual)$-2.77
CapEx CAGR (5Y)-47.98%
26-Week Price Return28.82%
Quick Ratio (Annual)8.68x
13-Week Price Return16.43%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.09x
Enterprise Value$5.49B
Book Value / Share Growth (5Y)0.91%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.42
3-Month Return Std Dev85.85%
Net Income / Employee (TTM)$-1,396,700
ROE (Last FY)-59.30%
EPS Basic Excl Extra (Annual)$-2.77
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.77
Receivables Turnover (Annual)0.00x
ROI (TTM)-68.16%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.78
Price vs S&P 500 (52W)69.83%
Year-to-Date Return22.38%
5-Day Price Return-5.33%
EPS Normalized (Annual)$-2.77
ROA (5Y Avg)-45.49%
Month-to-Date Return-6.58%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-2.92
ROI (5Y Avg)-50.27%
EPS Basic Excl Extra (TTM)$-2.77
P/TBV (Quarterly)18.77x
P/B Ratio (Annual)5.93x
Book Value / Share (Annual)$4.18
Price vs S&P 500 (13W)8.17%
Beta0.82x
Revenue / Share (TTM)$0.00
ROE (TTM)-68.16%
52-Week Low$14.32
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q4 26-0.73est. -0.61
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.17
4.13
4.13
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMVTImmunovant, Inc. Common Stock | — | — | B | $31.11 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases driven by pathogenic IgG antibodies. Its lead candidate, IMVT-1402, is an FcRn inhibitor designed to reduce circulating IgG levels by blocking the receptor responsible for antibody recycling. The company focuses on research, development, and manufacturing of its therapeutic pipeline targeting autoimmune indications.